Venture Capital

A new FDA-approved device offers a drug-free alternative for severe rheumatoid arthritis. Rush University is the first in Chicago to implant the system.

Tractor Beverage's Haymaker line earns a stringent purity certification, signaling a major retail pivot where 'organic' is no longer the final word.

The 'better-for-you' brand is making a massive retail play, adding new executives and launching innovative gummies to capture the $100B energy market.

With a key drug for a rare disease nearing the finish line, Spruce adds two industry veterans to navigate the high-stakes FDA approval process.

A new report reveals AI-powered disinformation is bypassing firewalls, costing billions. Experts say firms are dangerously unprepared for this new reality.

Estrella Immunopharma unveils promising Phase 1 data for its next-gen T-cell therapy, but can it overcome a crowded market and its own financial hurdles?

Eli Lilly partners with China's Zonsen PepLib, betting on its novel peptide platforms to fuel the next wave of therapies in oncology and metabolism.

A legacy manufacturer turned decades of dormant engineering files into a strategic asset, recovering 600 hours and boosting efficiency by 98% with AI.

New Medicare rules expand access to opioid alternatives, reshaping post-surgery recovery and rewarding companies at the forefront of pain management.

A new partnership aims to slash waste and streamline clinical trials, heralding a tech-driven transformation in the backbone of drug development.

Colonial Heights schools adopt AI gun detection to boost safety, but the tech faces scrutiny over its real-world effectiveness and privacy implications.

Catapult launches the portable Perch P2, a camera-based system using AI to track athlete performance anywhere, from the weight room to the field.

Novo Nordisk exec Karin Conde-Knape joins Valo as CSO, signaling a major validation for AI's role in creating next-generation medicines.

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.

Powersports giant Massimo Group's stock plummets after announcing a bold but risky plan to acquire an AI firm and enter the health robotics market.

A next-gen immunotherapy enters trials, hoping its safer design can unlock the immune system and form a potent combo against advanced solid tumors.

e.l.f. Cosmetics unveils its dramatic, star-studded Big Game spot, blending humor, culture, and a best-selling lip oil in a savvy marketing move.

A new binational challenge offers $70,000 in funding, calling on students and entrepreneurs to build the next wave of water technology solutions.

TeraWulf is acquiring old industrial sites in KY and MD, adding massive power capacity for the AI boom while aiming to stabilize regional energy grids.

Weeks after a rocky IPO, VR firm Virtuix will pitch investors on a dual-use strategy, hoping high-margin defense contracts and AI can justify steep losses.